Rationale for Frontline Ibrutinib +/- Rituximab in CLL

Hematology-oncology expert Ian W. Flinn, MD, PhD, discusses the rationale and data supporting the use of ibrutinib plus [or] minus rituximab as a frontline therapy in patients with chronic lymphocytic leukemia (CLL).

For more resources and information regarding anticancer targeted therapies:

targeted oncology,oncology,cancer,